Achieving Process Understanding and Control in Film Coating - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Achieving Process Understanding and Control in Film Coating
The authors describe a QbD study that was performed to optimize a coating system.

Pharmaceutical Technology
Volume 36, Issue 9, pp. s18-s21

QbD roadmap

A typical QbD exercise is to outline the process flow diagram and construct the process mapping to identify the key process input variables (KPIVs) and key process output variables (KPOVs). The relative importance of the KPIVs and KPOVs were assessed with a cause-and-effect (C&E) matrix. The KPOVs with the highest scores (e.g., in the top 20th percentile) were considered to be CQAs for which process specifications needed to be defined. The C&E matrix result showed that the blending uniformity before and after the addition of MCT was critical. The blend uniformity before MCT addition determined the blend uniformity after MCT addition. Therefore, there was only one CQA in the blending process. The detection sensitivity needed to determine the blend uniformity was based on visual detection by obtaining a blend drawdown. Visual detection under magnification, which can further ensure uniformity quality, is recommended. From the C&E matrix, the KPOVs with high scores (i.e., raw material charge and sample checking for blend uniformity) were defined as the CPPs. It is important to control the CPPs to achieve desirable quality. A failure mode effect analysis (FMEA) was performed based on the CPPs identified.

Coating QbD

Based on the FMEA assessment, the risk-priority number (RPN) was generated, and the raw-material charge had a high RPN. Corrective action plans were developed to control the raw-material charge procedure and ensure accuracy and execution of the production procedure. Similarly, the drawdown step was also a CPP. The RPN was not as severe compared with the raw material charge step, and a process-control procedure was also proposed. The C&E assessment indicated a completely dispersed Spectrablend II pink in water was a CQA. This CQA could be controlled by visual testing. All KPIVs were CPPs. The coating process had six process variables (i.e., coating temperature, spray rate, pan speed, atomization pressure, AIR pattern, and air flow).

Relative coating effect

The C&E assessment suggested coating efficiency, drying efficiency, and coating quality were the CQAs. Drying efficiency is a visual observation during coating and is dependent on the operator's experience. Coating quality can be quantitatively measured by colorimetry and other rheological tests. The C&E assessment suggested all six KVIPs had a significant effect. A FMEA assessment was performed.

FMEA for coating process

Tablet charge, air flow, coating temperature, spray rate, and pan speed needed to be controlled. Tablet-charge amount should be maximized according to the pan-coater design. Air flow was correlated to coating temperature and should be adjusted to the optimal setting to stabilize the coating temperature. Pan speed should be adjusted to have an ideal flow without excessive tumbling to cause tablet or coating chipping. The coating temperature and spray rate effect were more subjected to the coating material as previously described.


Critical quality attributes, such as color shade, gloss, slip, and adhesion, can be controlled by proper material and process specification. A QbD approach is a practical tool to understand and control quality and the process.

Eric Van Ness* is technical support manager, Beverly Schad is technical sales manager, Thomas Riley is formulations manager, and Brian Cheng is formulations scientist, all at Sensient Pharmaceutical Coating Systems, Saint Louis, MO, tel. 314.286.7135,

*To whom all correspondence should be addressed.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here